




Instance: composition-en-86f804709e3279dcca0da696e8a674dd
InstanceOf: CompositionUvEpi
Title: "Composition for opsumit Package Leaflet"
Description:  "Composition for opsumit Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpf082b236ec5dc5f46f11fee445feb390)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - opsumit"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Opsumit is and what it is used for</li>
<li>What you need to know before you take Opsumit</li>
<li>How to take Opsumit</li>
<li>Possible side effects</li>
<li>How to store Opsumit</li>
<li>Contents of the pack and other information</li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What opsumit is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What opsumit is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opsumit contains the active substance macitentan, which belongs to the class of medicines called 
 endothelin receptor antagonists .
Opsumit is used for the long-term treatment of pulmonary arterial hypertension (PAH) in adults; it can 
be used on its own or with other medicines for PAH. PAH is high blood pressure in the blood vessels 
that carry blood from the heart to the lungs (the pulmonary arteries). In people with PAH, these 
arteries get narrower, so the heart has to work harder to pump blood through them. This causes people 
to feel tired, dizzy, and short of breath.
Opsumit widens the pulmonary arteries, making it easier for the heart to pump blood through them. 
This lowers the blood pressure, relieves the symptoms and improves the course of the disease.</p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take opsumit"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take opsumit"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Opsumit</p>
<p>if you are allergic to macitentan, soya or any of the other ingredients of this medicine (listed in 
section 6).</p>
<p>if you are pregnant, if you are planning to become pregnant, or if you could become pregnant 
because you are not using reliable birth control (contraception). See section  Pregnancy and 
breastfeeding .</p>
<p>if you are breastfeeding. See section  Pregnancy and breastfeeding .</p>
<p>if you have liver disease or if you have very high levels of liver enzymes in your blood. Talk to 
your doctor, who will decide whether this medicine is suitable for you.
If any of these apply to you, please tell your doctor.
Warnings and precautions 
Talk to your doctor or pharmacist before taking Opsumit.
You will need blood tests, as indicated by your doctor:
Your doctor will take blood test before you start treatment with Opsumit and during treatment to test:</p>
<p>whether you have anaemia (a reduced number of red blood cells)</p>
<p>whether your liver is working properly
If you have anaemia (a reduced number of red blood cells), you may have the following signs:</p>
<p>dizziness </p>
<p>fatigue/malaise/weakness</p>
<p>fast heart rate, palpitations</p>
<p>pallor
If you notice any of these signs, tell your doctor.
Signs that your liver may not be working properly include:</p>
<p>feeling sick (nausea)</p>
<p>vomiting</p>
<p>fever </p>
<p>pain in your stomach (abdomen)</p>
<p>yellowing of your skin or the whites of your eyes (jaundice)</p>
<p>dark-coloured urine</p>
<p>itching of your skin</p>
<p>unusual tiredness or exhaustion (lethargy or fatigue)</p>
<p>flu-like syndrome (joint and muscle pain with fever)
If you notice any of these signs, tell your doctor immediately.
If you have kidney problems, talk to your doctor before using Opsumit. Macitentan may lead to more 
reduction of blood pressure and decrease in haemoglobin in patients with kidney problems.
In patients with pulmonary veno-occlusive disease (obstruction of the lung veins), the use of 
medicines for treatment of PAH, including Opsumit, may lead to pulmonary oedema. If you have 
signs of pulmonary oedema when using Opsumit, such as a sudden, important increase in 
breathlessness and low oxygen, tell your doctor immediately. Your doctor may perform additional 
tests, and will determine what treatment regimen is most suitable for you.
Children and adolescents
Do not give this medicine to children and adolescents below 18 years because Opsumit has not been 
tested in children.
Other medicines and Opsumit
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicine.
Opsumit can affect other medicines.
If you take Opsumit together with other medicines including those listed below, the effects of Opsumit 
or the other medicines might be altered. Please talk to your doctor or pharmacist if you are taking any 
of the following medicines:</p>
<p>rifampicin, clarithromycin, telithromycin, ciprofloxacin, erythromycin (antibiotics used to treat 
infections),</p>
<p>phenytoin (a medicine used to treat seizures),</p>
<p>carbamazepine (used to treat depression and epilepsy),</p>
<p>St. John s Wort (an herbal preparation used to treat depression),</p>
<p>ritonavir, saquinavir (used to treat HIV infections),</p>
<p>nefazodone (used to treat depression),</p>
<p>ketoconazole (except shampoo), fluconazole, itraconazole, miconazole, voriconazole (medicines 
used against fungal infections)</p>
<p>amiodarone (to control the heartbeat)</p>
<p>cyclosporine (used to prevent organ rejection after transplant)  </p>
<p>diltiazem, verapamil (to treat high blood pressure or specific heart problems)
Opsumit with food
If you are taking piperine as a dietary supplement, this may alter how the body responds to some 
medicinal products, including Opsumit. Please talk to your doctor or pharmacist should this be the 
case.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask 
your doctor for advice before taking this medicine.
Opsumit may harm unborn babies conceived before, during or soon after treatment.</p>
<p>If it is possible you could become pregnant, use a reliable form of birth control (contraception) 
while you are taking Opsumit. Talk to your doctor about this.</p>
<p>Do not take Opsumit if you are pregnant or planning to become pregnant.</p>
<p>If you become pregnant or think that you may be pregnant while you are taking Opsumit, or 
shortly after stopping Opsumit (up to 1 month), see your doctor immediately.
If you are a woman who could become pregnant, your doctor will ask you to take a pregnancy test 
before you start taking Opsumit and regularly (once a month) while you are taking Opsumit.
It is not known if Opsumit is transferred to breast milk. Do not breastfeed while you are taking 
Opsumit. Talk to your doctor about this.
Fertility
If you are a man taking Opsumit, it is possible that this medicine may lower your sperm count. Talk to 
your doctor if you have any questions or concerns about this.
Driving and using machines
Opsumit can cause side effects such as headaches and hypotension (listed in section 4), and the 
symptoms of your condition can also make you less fit to drive.
Opsumit contains lactose, lecithin from soya and sodium
Opsumit contains a sugar called lactose. If you have been told by your doctor that you have an 
intolerance to some sugars, contact your doctor before taking this medicine.
Opsumit contains lecithin derived from soya. If you are allergic to soya, do not use this medicine (see 
section 2  Do not take Opsumit ).
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 
 sodium-free .</p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take opsumit"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take opsumit"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opsumit should only be prescribed by a doctor experienced in the treatment of pulmonary arterial 
hypertension.
Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not 
sure.
The recommended dose of Opsumit is one 10 mg tablet, once a day. Swallow the whole tablet, with a 
glass of water, do not chew or break the tablet. You can take Opsumit with or without food. It is best 
to take the tablet at the same time each day.
If you take more Opsumit than you should
If you have taken more tablets than you have been told to take, you may experience headache, nausea, 
or vomiting. Ask your doctor for advice.
If you forget to take Opsumit
If you forget to take Opsumit, take a dose as soon as you remember, then continue to take your tablets 
at the usual times. Do not take a double dose to make up for a forgotten tablet.
If you stop taking Opsumit
Opsumit is a treatment that you will need to keep on taking to control your PAH. Do not stop taking 
Opsumit unless you have agreed this with your doctor.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.
Uncommon side effects (may affect up to 1 in 100 people)</p>
<p>Allergic reactions (swelling around the eyes, face, lips, tongue or throat, itching and/or rash)
If you notice any of these signs, tell your doctor immediately.
Very common side effects (may affect more than 1 in 10 people)</p>
<p>Anaemia (low number of red blood cells) or reduced haemoglobin</p>
<p>Headache</p>
<p>Bronchitis (inflammation of the airways)</p>
<p>Nasopharyngitis (inflammation of the throat and nasal passages)</p>
<p>Oedema (swelling), especially of the ankles and feet
Common side effects (may affect up to 1 in 10 people)</p>
<p>Pharyngitis (inflammation of the throat)</p>
<p>Influenza (flu)</p>
<p>Urinary tract infection (bladder infection)</p>
<p>Hypotension (low blood pressure)</p>
<p>Nasal congestion (blocked nose)</p>
<p>Elevated liver tests</p>
<p>Leukopenia (decreased white blood cell counts)</p>
<p>Thrombocytopenia (decreased blood platelet counts)</p>
<p>Flushing (redness of the skin)
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects you can help provide more information on the safety of 
this medicine.</p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store opsumit"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store opsumit"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children.
Do not use Opsumit after the expiry date which is stated on the carton and blister after  EXP . The 
expiry date refers to the last day of that month.
Do not store above 30 C.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to
throw away medicines you no longer require. These measures will help to protect the environment.</p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <h2>What Opsumit contains</h2>
<h2>The active substance is macitentan. Each tablet contains 10 mg macitentan.</h2>
<p>The other ingredients are lactose monohydrate (see section 2  Opsumit contains lactose, lecithin 
from soya and sodium ), microcrystalline cellulose (E460i), povidone, sodium starch glycolate
Type A (see section 2  Opsumit contains lactose, lecithin from soya and sodium ), magnesium 
stearate (E572), polysorbate 80 (E433), polyvinyl alcohol (E1203), titanium dioxide (E171), talc
(E553b), soya bean lecithin (E322) (see section 2  Opsumit contains lactose, lecithin from soya
and sodium ) and xanthan gum (E415).
What Opsumit looks like and contents of the pack
Opsumit 10 mg tablets are white to off-white, biconvex, round, film-coated tablets with  10  on both 
sides.
Opsumit is supplied as 10 mg film-coated tablets in blister packs of 15 or 30 tablets.
Not all pack sizes may be marketed.
Marketing Authorisation Holder
Janssen-Cilag International NV
Turnhoutseweg B-2340 Beerse
Belgium
Manufacturer
Janssen Pharmaceutica NV
Turnhoutseweg B-2340 Beerse
Belgium
For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder:
Belgi /Belgique/Belgien
Janssen-Cilag NV
T l/Tel: +32 14 64 94 janssen@jacbe.jnj.com
Lietuva
UAB "JOHNSON &amp; JOHNSON"
Tel: +370 5 278 68 lt@its.jnj.com</p>
<p>&amp;    <br />
 .: +359 2 489 94 jjsafety@its.jnj.com
Luxembourg/Luxemburg
Janssen-Cilag NV
T l/Tel: +32 14 64 94 janssen@jacbe.jnj.com
 esk  republika
Janssen-Cilag s.r.o.
Tel: +420 227 012 Magyarorsz g
Janssen-Cilag Kft.
Tel.: +36 1 884 2janssenhu@its.jnj.com
Danmark
Janssen-Cilag A/S
Tlf: +45 4594 8jacdk@its.jnj.com
Malta
AM MANGION LTD
Tel: +356 2397 6Deutschland
Janssen-Cilag GmbH
Tel: +49 2137 955 jancil@its.jnj.com
Nederland
Janssen-Cilag B.V.
Tel: +31 76 711 1janssen@jacnl.jnj.com
Eesti
UAB "JOHNSON &amp; JOHNSON" Eesti filiaal
Tel: +372 617 7ee@its.jnj.com
Norge
Janssen-Cilag AS
Tlf: +47 24 12 65 jacno@its.jnj.com</p>
<p>Janssen-Cilag    . . . .
 : +30 210 80 90  sterreich
Janssen-Cilag Pharma GmbH
Tel: +43 1 610 Espa a
Janssen-Cilag, S.A.
Tel: +34 91 722 81 contacto@its.jnj.com
Polska
Janssen-Cilag Polska Sp. z o.o.
Tel.: +48 22 237 60 France
Janssen-Cilag
T l: 0 800 25 50 75 / +33 1 55 00 40 medisource@its.jnj.com
Portugal
Janssen-Cilag Farmac utica, Lda.
Tel: +351 214 368 Hrvatska
Johnson &amp; Johnson S.E. d.o.o.
Tel: +385 1 6610 jjsafety@JNJCR.JNJ.com
Rom nia
Johnson &amp; Johnson Rom nia SRL
Tel: +40 21 207 1Ireland
Janssen Sciences Ireland UC
Tel: +353 1 800 709 Slovenija
Johnson &amp; Johnson d.o.o.
Tel: +386 1 401 18 Janssen_safety_slo@its.jnj.com
 sland
Janssen-Cilag AB
c/o Vistor hf.
S mi: +354 535 7janssen@vistor.is
Slovensk  republika
Johnson &amp; Johnson, s.r.o.
Tel: +421 232 408 Italia
Janssen-Cilag SpA
Tel: 800.688.777 / +39 02 2510 1
janssenita@its.jnj.com
Suomi/Finland
Janssen-Cilag Oy
Puh/Tel: +358 207 531 jacfi@its.jnj.com</p>
<p>: +357 22 207 Sverige
Janssen-Cilag AB
Tfn: +46 8 626 50 jacse@its.jnj.com
Latvija
UAB "JOHNSON &amp; JOHNSON" fili le Latvij 
Tel: +371 678 93lv@its.jnj.com
United Kingdom (Northern Ireland)
Janssen Sciences Ireland UC
Tel: +44 1 494 567 This leaflet was last revised in
Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-86f804709e3279dcca0da696e8a674dd
InstanceOf: CompositionUvEpi
Title: "Composition for opsumit Package Leaflet"
Description:  "Composition for opsumit Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpf082b236ec5dc5f46f11fee445feb390)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - opsumit"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen
1. Virkning og anvendelse
2. Det skal du vide, før du begynder at tage Opsumit
3. Sådan skal du tage Opsumit
4. Bivirkninger
5. Opbevaring
6. Pakningsstørrelser og yderligere oplysninger</p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What opsumit is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What opsumit is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opsumit indeholder det aktive stof macitentan, der tilhører en gruppe af lægemidler, der kaldes 
"endothelinreceptorantagonister".
Opsumit anvendes til langvarig behandling af pulmonal arteriel hypertension (PAH) hos voksne. Det 
kan anvendes alene eller sammen med anden medicin mod PAH. PAH er højt blodtryk i de blodkar, 
der transporterer blodet fra hjertet til lungerne (lungearterierne). Hos personer, der har PAH, bliver 
disse arterier smallere, så hjertet skal arbejde hårdere for at pumpe blod igennem dem. Dette forårsager 
træthed, svimmelhed og åndenød.
Opsumit udvider lungearterierne, så det bliver nemmere for hjertet at pumpe blod igennem dem. Det 
får blodtrykket til at falde, lindrer symptomerne og forbedrer sygdomsforløbet.</p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take opsumit"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take opsumit"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Opsumit

hvis du er allergisk over for macitentan, soja eller et af de øvrige indholdsstoffer i Opsumit
(angivet i punkt 6).

hvis du er gravid, planlægger at blive gravid, eller kan blive gravid, fordi du ikke anvender en 
sikker præventionsmetode (kontraception). Se afsnittet "Graviditet og amning".

hvis du ammer. Se afsnittet "Graviditet og amning".

hvis du har en leversygdom, eller hvis du har meget høje niveauer af leverenzymer i dit blod.
Kontakt lægen, som vil vurdere, hvorvidt dette lægemiddel er egnet til dig.
Kontakt lægen, hvis noget af ovennævnte gør sig gældende for dig.
27
Advarsler og forsigtighedsregler
Kontakt lægen eller apotekspersonalet, før du tager Opsumit.
Du skal have taget blodprøver i henhold til lægens anvisninger:
Lægen vil tage nogle blodprøver, før du starter behandlingen med Opsumit og under behandlingen, for 
at kontrollere:

Om du har blodmangel (nedsat antal røde blodlegemer).

Om din lever fungerer korrekt
Hvis du har blodmangel (nedsat antal røde blodlegemer), kan du have følgende tegn:

Svimmelhed

Træthed/utilpashed/svaghed

Hurtig puls, hjertebanken

Bleghed
Kontakt lægen, hvis du bemærker nogen af disse tegn.
Tegn på, at din lever ikke fungerer korrekt, omfatter:

Kvalme

Opkastning

Feber

Mavesmerter 

Gulfarvning af huden og det hvide i øjnene (gulsot)

Mørkfarvet urin

Kløe i huden

Usædvanlig træthed eller udmattelse (letargi eller træthed)

Influenzalignende syndrom (led- og muskelsmerter med feber)
Kontakt omgående lægen, hvis du bemærker et eller flere af disse tegn.
Kontakt lægen, før du begynder at bruge Opsumit, hvis du har nyreproblemer. Macitentan kan 
medføre yderligere fald i blodtrykket og fald i hæmoglobin hos patienter med nyreproblemer.
Hos patienter med pulmonal venookklusiv sygdom (tilstopning af lungevenerne) kan brug af 
lægemidler til behandling af PAH, herunder Opsumit, medføre lungeødem. Kontakt omgående 
lægen, hvis du får tegn på lungeødem, såsom en pludselig, markant forværring af stakåndethed og lavt 
iltniveau, mens du bruger Opsumit. Din læge vil eventuelt foretage yderligere test og bestemme, 
hvilken behandling der er bedst for dig.
Børn og unge
Giv ikke dette lægemiddel til børn og unge under 18 år, da Opsumit ikke er blevet undersøgt hos børn.
Brug af anden medicin sammen med Opsumit
Fortæl det altid til lægen eller apotekspersonalet, hvis du tager anden medicin, for nylig har taget 
anden medicin eller planlægger at tage anden medicin. Opsumit kan påvirke andre lægemidler.
Hvis du tager Opsumit sammen med andre lægemidler, herunder nedennævnte lægemidler, kan 
virkningen af Opsumit eller de andre lægemidler blive ændret. Kontakt lægen eller apotekspersonalet, 
hvis du tager et eller flere af følgende lægemidler:

rifampicin, clarithromycin, telithromycin, ciprofloxacin, erythromycin (antibiotika, der 
anvendes til behandling af infektioner)

phenytoin (et lægemiddel, der anvendes til behandling af krampeanfald)

carbamazepin (anvendes til behandling af depression og epilepsi)

prikbladet perikon (et urtepræparat, der anvendes til behandling af depression)
28

ritonavir, saquinavir (anvendes til behandling af hiv-infektioner)

nefazodon (anvendes til behandling af depression)

ketoconazol (undtagen shampoo), fluconazol, itraconazol, miconazol, voriconazol (lægemidler, 
der anvendes mod svampeinfektioner)

amiodaron (anvendes til at styre hjerterytmen)

ciclosporin (anvendes til at forebygge afstødning af organer efter transplantation)

diltiazem, verapamil (anvendes til at behandle for højt blodtryk eller specifikke hjerteproblemer)
Brug af Opsumit sammen med mad
Hvis du tager piperin som kosttilskud, kan det ændre den måde, som kroppen reagerer på visse 
lægemidler på, herunder Opsumit. Tal med lægen eller apotekspersonalet, hvis dette er tilfældet.
Graviditet og amning
Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal 
du spørge din læge til råds, før du tager dette lægemiddel.
Opsumit kan skade ufødte børn, der undfanges før, under eller kort efter behandlingen.

Hvis du er i den fødedygtige alder, skal du anvende en sikker præventionsmetode 
(kontraception), så længe du tager Opsumit. Tal med lægen herom.

Tag ikke Opsumit, hvis du er gravid eller planlægger at blive gravid.

Hvis du bliver gravid, eller får mistanke om, at du er gravid, mens du er i behandling med 
Opsumit, eller kort tid efter du er stoppet med at tage Opsumit (op til 1 måned), skal du straks 
kontakte lægen.
Hvis du er kvinde og i den fødedygtige alder vil lægen bede dig om at tage en graviditetstest, inden du 
starter med at tage Opsumit, og med jævne mellemrum (en gang om måneden) under behandlingen 
med Opsumit.
Det vides ikke, om Opsumit overføres til modermælken. Du må ikke amme, mens du er i behandling 
med Opsumit. Tal med lægen herom. 
Frugtbarhed
Hvis du er mand og tager Opsumit, er det muligt, at medicinen kan nedsætte antallet af sædceller. Tal 
med din læge, hvis du har spørgsmål eller bekymringer herom.
Trafik- og arbejdssikkerhed
Opsumit kan forårsage bivirkninger, såsom hovedpine og lavt blodtryk (anført i punkt 4), og de 
symptomer, du har i forbindelse med din sygdom, kan også nedsætte din evne til at føre motorkøretøj.
Opsumit indeholder lactose, lecithin udledt fra soja og natrium
Opsumit indeholder en sukkerart, der kaldes for lactose. Kontakt lægen, før du tager dette lægemiddel, 
hvis lægen har fortalt dig, at du ikke tåler visse sukkerarter.
Opsumit indeholder lecithin, der er udledt fra soja. Hvis du er allergisk over for soja, må du ikke bruge 
dette lægemiddel (se afsnit 2 "Tag ikke Opsumit").
Dette lægemiddel indeholder mindre end 1 mmol (23 mg) natrium pr. tablet, dvs. det er i det 
væsentlige natriumfrit.</p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take opsumit"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take opsumit"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opsumit bør kun ordineres af en læge med erfaring i behandling af pulmonal arteriel hypertension.
Tag altid lægemidlet nøjagtigt efter lægens anvisning. Er du i tvivl, så spørg lægen.
29
Den anbefalede dosis af Opsumit er én 10 mg tablet én gang dagligt. Tabletten skal synkes hel med et 
glas vand. Tabletten må ikke tygges eller deles. Du kan tage Opsumit sammen med eller uden mad. 
Det er bedst at tage tabletten på samme tidspunkt hver dag.
Hvis du har taget for meget Opsumit
Hvis du har taget flere tabletter end du har fået besked på at tage, kan du opleve hovedpine, kvalme 
eller opkastning. Spørg din læge til råds.
Hvis du har glemt at tage Opsumit
Hvis du glemmer at tage Opsumit, skal du tage en dosis, så snart du kommer i tanker om det. Herefter 
skal du fortsætte med at tage tabletterne på det sædvanlige tidspunkt. Du må ikke tage en dobbeltdosis 
som erstatning for den glemte tablet.
Hvis du holder op med at tage Opsumit
Opsumit er en behandling, som du skal blive ved med at tage for at holde din PAH under kontrol. Du 
må ikke stoppe med at tage Opsumit, medmindre du har aftalt det med lægen.
Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om.</p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger.
Ikke almindelige bivirkninger (kan påvirke op til 1 ud af 100 brugere)

Allergiske reaktioner (hævde øjenomgivelser, hævelser i ansigt, læber, tunge eller svælg, kløe 
og/eller udslæt). 
Kontakt omgående lægen, hvis du bemærker nogen af disse tegn.
Meget almindelige bivirkninger (kan påvirke mere end 1 ud af 10 brugere)

Blodmangel (lavt antal røde blodlegemer) eller nedsat hæmoglobin

Hovedpine

Bronkitis (betændelse i luftvejene)

Snue (betændelse i svælg og næse)

Ødem (hævelse), særligt på ankler og fødder
Almindelige bivirkninger (kan påvirke op til 1 ud af 10 brugere)

Svælgkatar (halsbetændelse)

Influenza

Urinvejsinfektion (blærebetændelse)

Hypotension (lavt blodtryk)

Nasal obstruktion (tilstoppet næse)

Forhøjede levertal

Leukopeni (nedsat antal hvide blodlegemer)

Trombocytopeni (nedsat antal blodplader)

Blussen (hudrødme)
Indberetning af bivirkninger
Hvis du oplever bivirkninger, bør du tale med din læge, eller apotekspersonalet. Dette gælder også 
mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også 
indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i 
Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information 
om sikkerheden af dette lægemiddel.</p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store opsumit"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store opsumit"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>30
Opbevar lægemidlet utilgængeligt for børn.
Brug ikke Opsumit efter den udløbsdato, der står på kartonen og blisteren efter EXP. Udløbsdatoen er 
den sidste dag i den nævnte måned.
Må ikke opbevares ved temperaturer over 30 ºC.
Spørg apotekspersonalet, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke
smide medicinrester i afløbet, toilettet eller skraldespanden.</p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <h2>Opsumit indeholder:</h2>
<h2>Aktivt stof: macitentan. Hver tablet indeholder 10 mg macitentan.</h2>
<p>Øvrige indholdsstoffer: lactosemonohydrat (se afsnit 2 "Opsumit indeholder lactose, lecithin 
udledt fra soja og natrium"), mikrokrystallinsk cellulose (E460i), povidon, 
natriumstivelsesglycolat type A (se afsnit 2 "Opsumit indeholder lactose, lecithin udledt fra 
soja og natrium"), magnesiumstearat (E572), polysorbat 80 (E433), polyvinylalkohol (E1203), 
titandioxid (E171), talcum (E553b), sojalecithin (E322) (se afsnit 2 "Opsumit indeholder 
lactose, lecithin udledt fra soja og natrium") og xanthangummi (E415).
Udseende og pakningsstørrelser
Opsumit 10 mg tabletter er hvide til råhvide, bikonvekse, runde, filmovertrukne tabletter, der er præget 
med "10" på begge sider.
Opsumit leveres som 10 mg filmovertrukne tabletter i blisterpakninger med 15 eller 30 tabletter.
Ikke alle pakningsstørrelser er nødvendigvis markedsført.
Indehaver af markedsføringstilladelsen
Janssen-Cilag International NV
Turnhoutseweg 30
B-2340 Beerse
Belgien
Fremstiller
Janssen Pharmaceutica NV
Turnhoutseweg 30
B-2340 Beerse
Belgien
Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen:
België/Belgique/Belgien
Janssen-Cilag NV
Tél/Tel: +32 14 64 94 11
janssen@jacbe.jnj.com
Lietuva
UAB "JOHNSON &amp; JOHNSON"
Tel: +370 5 278 68 88
lt@its.jnj.com
България
„Джонсън &amp; Джонсън България" ЕООД
Тел.: +359 2 489 94 00
jjsafety@its.jnj.com
Luxembourg/Luxemburg
Janssen-Cilag NV
Tél/Tel: +32 14 64 94 11
janssen@jacbe.jnj.com
31
Česká republika
Janssen-Cilag s.r.o.
Tel: +420 227 012 227
Magyarország
Janssen-Cilag Kft.
Tel.: +36 1 884 2858
janssenhu@its.jnj.com
Danmark
Janssen-Cilag A/S
Tlf: +45 4594 8282
jacdk@its.jnj.com
Malta
AM MANGION LTD
Tel: +356 2397 6000
Deutschland
Janssen-Cilag GmbH
Tel: +49 2137 955 955
jancil@its.jnj.com
Nederland
Janssen-Cilag B.V.
Tel: +31 76 711 1111
janssen@jacnl.jnj.com
Eesti
UAB "JOHNSON &amp; JOHNSON" Eesti filiaal
Tel: +372 617 7410
ee@its.jnj.com
Norge
Janssen-Cilag AS
Tlf: +47 24 12 65 00
jacno@its.jnj.com
Ελλάδα
Janssen-Cilag Φαρμακευτική Α.Ε.Β.Ε.
Τηλ: +30 210 80 90 000
Österreich
Janssen-Cilag Pharma GmbH
Tel: +43 1 610 300
España
Janssen-Cilag, S.A.
Tel: +34 91 722 81 contacto@its.jnj.com
Polska
Janssen-Cilag Polska Sp. z o.o.
Tel.: +48 22 237 60 00
France
Janssen-Cilag
Tél: 0 800 25 50 75 / +33 1 55 00 40 03
medisource@its.jnj.com
Portugal
Janssen-Cilag Farmacêutica, Lda.
Tel: +351 214 368 600
Hrvatska
Johnson &amp; Johnson S.E. d.o.o.
Tel: +385 1 6610 700
jjsafety@JNJCR.JNJ.com
România
Johnson &amp; Johnson România SRL
Tel: +40 21 207 1800
Ireland
Janssen Sciences Ireland UC
Tel: +353 1 800 709 122
Slovenija
Johnson &amp; Johnson d.o.o.
Tel: +386 1 401 18 00
Janssen_safety_slo@its.jnj.com
Ísland
Janssen-Cilag AB
c/o Vistor hf.
Sími: +354 535 7000
janssen@vistor.is
Slovenská republika
Johnson &amp; Johnson, s.r.o.
Tel: +421 232 408 400
Italia
Janssen-Cilag SpA
Tel: 800.688.777 / +39 02 2510 1
janssenita@its.jnj.com
Suomi/Finland
Janssen-Cilag Oy
Puh/Tel: +358 207 531 300
jacfi@its.jnj.com
32
Κύπρος
Βαρνάβας Χατζηπαναγής Λτδ
Τηλ: +357 22 207 700
Sverige
Janssen-Cilag AB
Tfn: +46 8 626 50 00
jacse@its.jnj.com
Latvija
UAB "JOHNSON &amp; JOHNSON" filiāle Latvijā
Tel: +371 678 93561
lv@its.jnj.com
United Kingdom (Northern Ireland)
Janssen Sciences Ireland UC
Tel: +44 1 494 567 444
Denne indlægsseddel blev senest ændret
Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu.</p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-86f804709e3279dcca0da696e8a674dd
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for opsumit Package Leaflet for language en"
Description: "ePI document Bundle for opsumit Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-86f804709e3279dcca0da696e8a674dd"
* entry[0].resource = composition-en-86f804709e3279dcca0da696e8a674dd

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp86f804709e3279dcca0da696e8a674dd"
* entry[=].resource = mp86f804709e3279dcca0da696e8a674dd
                            
                    
Instance: bundlepackageleaflet-da-86f804709e3279dcca0da696e8a674dd
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for opsumit Package Leaflet for language da"
Description: "ePI document Bundle for opsumit Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-86f804709e3279dcca0da696e8a674dd"
* entry[0].resource = composition-da-86f804709e3279dcca0da696e8a674dd

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp86f804709e3279dcca0da696e8a674dd"
* entry[=].resource = mp86f804709e3279dcca0da696e8a674dd
                            
                    



Instance: mp86f804709e3279dcca0da696e8a674dd
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Opsumit 10 mg film-coated tablets"
Description: "Opsumit 10 mg film-coated tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/13/893/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Opsumit 10 mg film-coated tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 86f804709e3279dcca0da696e8a674ddListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "opsumit"

* status = #current
* mode = #working

* title = "List of all ePIs associated with opsumit"

* subject = Reference(mpf082b236ec5dc5f46f11fee445feb390)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#opsumit "opsumit"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-86f804709e3279dcca0da696e8a674dd) // opsumit en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-86f804709e3279dcca0da696e8a674dd) // opsumit da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-86f804709e3279dcca0da696e8a674dd
InstanceOf: List

* insert 86f804709e3279dcca0da696e8a674ddListRuleset
    